Table 2.
Patient characteristics
| t-MDS (n=28) | de novo MDS (n=147) | p value | |
|---|---|---|---|
| Age (years) | 69 (37–81) | 70 (14–91) | 0.2061 |
| Men:Women | 17:11 | 106:41 | 0.2610 |
| Hemoglobin (g/L) | 96 (72–128) | 97 (60–143) | 0.5798 |
| Mean corpuscular volume (femtoliter) | 92 (79–109) | 94 (70–120) | 0.6973 |
| White blood cell (× 109/L) | 3.1 (0.5–24.9) | 2.9 (0.1–14.3) | 0.9497 |
| Absolute neutrophil count (× 109/L) | 1.2 (0.3–15.4) | 1.4 (0–10.0) | 0.9641 |
| Platelet (× 109/L) | 46.5 (17.0–257.0) | 65.0 (3.0–614.0) | 0.1423 |
| BM blasts (%) | 4.5 (0–18.0) | 5.0 (0–19.0) | 0.4926 |
| BM cellularity (%) | 40 (20–100) | 60 (5–100) | 0.2364 |
| Cytogenetic risk, n (%) | 0.0005 | ||
| Good | 4 (14.3%) | 74 (50.3%) | |
| Intermediate | 4 (14.3%) | 28 (19.0%) | |
| Poor | 18 (64.3%) | 45 (30.6%) | |
| n/a | 2 (7.1%) | 0 (0.0%) | |
| WHO classification, n (%) | |||
| RCUD | 0 | 1 (0.7%) | |
| RARS | 0 | 2 (1.4%) | |
| RCMD | 12 (42.8%) | 58 (39.5%) | |
| RAEB-1 | 8 (28.6%) | 37 (25.2%) | |
| RAEB-2 | 8 (28.6%) | 47 (32.0%) | |
| MDS with isolated del 5q | 0 | 2 (1.4%) |
| t-AML (n=42) | de novo AML (n=281) | p value | |
|---|---|---|---|
| Age (years) | 66.5 (18.0–87.0) | 65.0 (1.0–92.0) | 0.3842 |
| Men:Women | 24:18 | 165:116 | 0.8678 |
| Hemoglobin (g/L) | 91 (60–118) | 9.3 (56–154) | 0.5081 |
| Mean corpuscular volume (femtoliter) | 91.5 (78.0–112.0) | 91 (68–112) | 0.6599 |
| White blood cell (× 109/L) | 2.3 (0.3–93.9) | 3.5 (0.3–255.0) | 0.0819 |
| Platelet (× 109/L) | 33.0 (7.0–394.0) | 47.0 (3.0–1069.0) | 0.1446 |
| BM blasts (%) | 31 (2–91) | 39 (0–99) | 0.1883 |
| BM cellularity (%) | 60 (5–100) | 80 (5–100) | 0.1693 |
| UKMRC cytogenetic risk, n (%) | 0.0006 | ||
| Favorable | 2 (4.8%) | 26 (9.3%) | |
| Intermediate | 11 (26.2%) | 154 (54.8%) | |
| Unfavorable | 28 (66.7%) | 94 (33.5%) | |
| n/a | 1 (2.4%) | 7 (2.5%) |
BM, bone marrow; n/a, non-available; WHO, World Health Organization; UKMRC, United Kingdom Medical Research Council; RCUD; refractory cytopenia with unilineage dysplasia, RARS; refractory anemia with ring sideroblasts, RCMD; refractory cytopenia with multilineage dysplasia, RAEB; refractory anemia with excess blasts